4-Methylmorpholine → benzhydryl (6R,7R)-7-[[(2Z)-2-[2-[(2-methylpropan-2-yl)oxycarbonylamino]-1,3-thiazol-4-yl]-2-trityloxyiminoacetyl]amino]-3-methylsulfonyloxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate

HRID 1707435ノート

反応式

HRID 1707435 の反応式
[C:1]([O:5][C:6]([NH:8][C:9]1[S:10][CH:11]=[C:12](/[C:14](=[N:18]/[O:19][C:20]([C:33]2[CH:38]=[CH:37][CH:36]=[CH:35][CH:34]=2)([C:27]2[CH:32]=[CH:31][CH:30]=[CH:29][CH:28]=2)[C:21]2[CH:26]=[CH:25][CH:24]=[CH:23][CH:22]=2)/[C:15](O)=[O:16])[N:13]=1)=[O:7])([CH3:4])([CH3:3])[CH3:2].CN1CCOCC1.Cl.[C:47]1([CH:53]([O:60][C:61]([C:63]2[N:68]3[C:69](=[O:72])[C@@H:70]([NH2:71])[C@H:67]3[S:66][CH2:65][C:64]=2[O:73][S:74]([CH3:77])(=[O:76])=[O:75])=[O:62])[C:54]2[CH:59]=[CH:58][CH:57]=[CH:56][CH:55]=2)[CH:52]=[CH:51][CH:50]=[CH:49][CH:48]=1.Cl.C(N=C=NCCCN(C)C)C>ClCCl.O>[C:47]1([CH:53]([O:60][C:61]([C:63]2[N:68]3[C:69](=[O:72])[C@@H:70]([NH:71][C:15](=[O:16])/[C:14](/[C:12]4[N:13]=[C:9]([NH:8][C:6]([O:5][C:1]([CH3:3])([CH3:2])[CH3:4])=[O:7])[S:10][CH:11]=4)=[N:18]\[O:19][C:20]([C:27]4[CH:32]=[CH:31][CH:30]=[CH:29][CH:28]=4)([C:21]4[CH:26]=[CH:25][CH:24]=[CH:23][CH:22]=4)[C:33]4[CH:38]=[CH:37][CH:36]=[CH:35][CH:34]=4)[C@H:67]3[S:66][CH2:65][C:64]=2[O:73][S:74]([CH3:77])(=[O:76])=[O:75])=[O:62])[C:54]2[CH:55]=[CH:56][CH:57]=[CH:58][CH:59]=2)[CH:48]=[CH:49][CH:50]=[CH:51][CH:52]=1

参加物

7

反応物 4

HCID 79724-MethylmorpholineHCID 27239391,3-Propanediamine, N'-(ethylcarbonimidoyl)-N,N-dimethyl-, monohydrochlorideHCID 10459636(Z)-2-(2-Boc-aminothiazole-4-yl-)-2-trityloxyiminoacetic acidHCID 883013187beta-Amino-3-methanesulfonyloxy-3-cephem-4-carboxylic acid diphenylmethyl ester hydrochloride

生成物 1

HCID 10260338benzhydryl (6R,7R)-7-[[(2Z)-2-[2-[(2-methylpropan-2-yl)oxycarbonylamino]-1,3-thiazol-4-yl]-2-trityloxyiminoacetyl]amino]-3-methylsulfonyloxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate収率 79%

試薬・触媒・溶媒 2

HCID 962Water溶媒HCID 6344Dichloromethane溶媒

実験手順

To a suspension of (Z)-2-(2-t-butoxycarbonylaminothiazol-4-yl)-2-trityloxyiminoacetic acid (41.7 g: 78.8 mMol.) in dichloromethane (600 ml) is added at -30° C. N-methylmorpholine (7.575 g: 75 mMol.), and the mixture is stirred for 10 minutes, mixed with 7β-amino-3-methanesulfonyloxy-3-cephem-4-carboxylic acid diphenylmethyl ester hydrochloride (37.27 g: 75 mMol.), is stirred at the same temperature for 50 minutes, mixed with 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (14.38 g: 75 mMol.), stirred under ice cooling for 3 hours, diluted with water, and extracted with ethyl acetate. The extract is washed with water, dried, and concentrated under reduced pressure. The residue is purified by silica gel chromatography (toluene containing 0.5% acetic acid: ethyl acetate=10:1) and the eluate is treated with etherhexane to give 7β-[(Z)-2-(2-t-butoxycarbonylaminothiazol-4-yl)-2-trityloxyiminoacetamido]-3-methanesulfonyloxy-3-cephem-4-carboxylic acid diphenylmethyl ester (57.42 g). Colorless powder. Yield: 79 %. This product contains ca. 5% of the 2-cephem isomer.

後処理

  1. additionis added at -30° C
  2. stirringstirred under ice cooling for 3 hours
  3. extractionextracted with ethyl acetate
  4. washThe extract is washed with water
  5. customdried
  6. concentrationconcentrated under reduced pressure
  7. customThe residue is purified by silica gel chromatography (toluene containing 0.5% acetic acid: ethyl acetate=10:1)
  8. additionthe eluate is treated with etherhexane

出典と根拠

ORDレコード
ord-7642c410d47141fbbc91fb260f408e07
出典データセット
uspto-grants-1994_10
特許番号
US05352792

反応ノート

読み込み中…